2024
Outcomes of repeat conventional transarterial chemoembolization in patients with liver metastases
Ghabili K, Windham-Herman A, Konstantinidis M, Murali N, Borde T, Adam L, Laage-Gaupp F, Lin M, Chapiro J, Georgiades C, Nezami N. Outcomes of repeat conventional transarterial chemoembolization in patients with liver metastases. Annals Of Hepatology 2024, 29: 101529. PMID: 39033928, PMCID: PMC11558520, DOI: 10.1016/j.aohep.2024.101529.Peer-Reviewed Original ResearchConventional transarterial chemoembolizationLiver metastasesNeuroendocrine tumorsColorectal carcinomaTransarterial chemoembolizationOverall survivalLung cancerAssociated with improved patient survivalManagement of liver metastasesMetastatic liver lesionsSingle-institution analysisNonresponding patientsSurvival outcomesPatient survivalResponse assessmentTarget lesionsMetastasisLiver lesionsPatientsResponse rateChemoembolizationSurvivalLiverLesionsCancer
2020
Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer
Stark S, Wang C, Savic LJ, Letzen B, Schobert I, Miszczuk M, Murali N, Oestmann P, Gebauer B, Lin M, Duncan J, Schlachter T, Chapiro J. Automated feature quantification of Lipiodol as imaging biomarker to predict therapeutic efficacy of conventional transarterial chemoembolization of liver cancer. Scientific Reports 2020, 10: 18026. PMID: 33093524, PMCID: PMC7582153, DOI: 10.1038/s41598-020-75120-7.Peer-Reviewed Original ResearchConceptsConventional transarterial chemoembolizationLipiodol depositionTransarterial chemoembolizationLiver cancerPeripheral depositionLipiodol depositsTherapeutic efficacyNecrotic tumor areasBaseline MRITherapy optionsTumor responseTreatment responseTumor volumeLiver lesionsLipiodolH postTumor areaH-CTHounsfield unitsBiomarkersChemoembolizationHigh rateTumorsCancerImproved response